Research
Dr. Joy Feng is an Associate Professor in the Department of Pediatrics and an Associate Director in the Division of the Laboratory of Biochemical Pharmacology (LOBP). She joined Emory in February 2025 and brought 25 years of expertise and experience in pre-clinical drug discovery in HIV, HCV, respiratory viruses, and emerging viruses at a leading pharmaceutical company. Joy is one of the inventors of Remdesivir, the first FDA-approved antiviral to treat COVID, and Obeldesivir, the orally available form under development for emerging viruses. Joy’s primary research interests are antiviral nucleoside and nucleotide analogs, viral polymerases, drug resistance, toxicity and off-target evaluation/mechanism of action, and drug metabolizing enzymes/activation pathways, but most importantly, how to advance a drug from bench to bed to address the unmet medical needs.